ress Release
MDxHealth Reports Fourth Quarter and Fiscal Year 2014 Results
ConfirmMDx Full Year Revenue and Case Volume Continue Excellent Growth Trends
IRVINE, CA, and HERSTAL, BELGIUM - 8:00 AM, February 26, 2015 - MDxHealth SA (Euronext: MDXH.BR), today announced results for the fourth quarter and the fiscal year ended December 31, 2014.
Business Highlights
ConfirmMDx for Prostate Cancer
ConfirmMDx revenue increased 152% from $3.7 million to $9.4 million in 2014
ConfirmMDx revenue for Q4 doubled to $2.4 million compared to $1.2 million in the same period last year
Total full year revenue increased to $11.7 million in 2014 versus $7.6 million in 2013
Recorded a 76% increase in annual ConfirmMDx case volume, with 12,300 patients tested in 2014 compared to nearly 7,000 patients tested in 2013
In Q4, ConfirmMDx case volume increased 46% to more than 3,300 tests, compared to approximately 2,300 tests in Q4 2013
Published ConfirmMDx clinical utility study in the journal of in American Health and Drug Benefits
Published ConfirmMDx DOCUMENT validation study in the Journal of Urology
Signed marketing agreements, with Long Island Pathology, Inc., American Pathology Partners, and Miraca Life Sciences (MLS) to co-promote ConfirmMDx
Signed exclusive distribution agreement with Teva Pharmaceutical Ltd. for Israel
Signed reimbursement agreements with PPO providers Prime Health Services, Inc., Galaxy Health Network Ancillary Care Services (ACS), and Consilium, LLC
Palmetto GBA issued a Medicare coverage determination (LCD) for ConfirmMDx